Loading

Cannabis Caucus

  • by Justin Strekal, NORML Political Director September 7, 2017

    FBScorecardLate Wednesday night, the House Rules Committee led by prohibitionist Representative Pete Sessions (R-TX) blocked multiple amendments related to marijuana from receiving consideration by the full House, thus ending their consideration and silencing the ability for the lower chamber to offer protections from Attorney General Jeff Sessions when it comes to cannabis.

    Amendments included: ending the federal incentive to revoke drivers licenses from those charged with marijuana offenses; protections for states that have implemented hemp programs; a reduction in funding for the DEA’s cannabis eradication program; expanded access to researchersprotections for banks to provide services to marijuana businesses; allowing the District of Columbia to implement adult-use sales, and expanded protections to the eight states that have outright legalized marijuana.

    Most notably, the amendment offered by Representatives Dana RohrabacherEarl Blumenauer, and other allies in the House had again offered the Rohrabacher-Blumenauer amendment to continue to protect lawful state medical marijuana programs from the federal government. Specifically, the language maintains that federal funds cannot be used to prevent states from “implementing their own state laws that authorize the use, distribution, possession or cultivation of medical marijuana.”

    Representatives Blumenauer and Rohrabacher released the following statement in response:

    “By blocking our amendment, Committee leadership is putting at risk the millions of patients who rely on medical marijuana for treatment, as well as the clinics and businesses that support them. This decision goes against the will of the American people, who overwhelmingly oppose federal interference with state marijuana laws. These critical protections are supported by a majority of our colleagues on both sides of the aisle. There’s no question: If a vote were allowed, our amendment would pass on the House floor, as it has several times before.

    “Our fight to protect medical marijuana patients is far from over. The marijuana reform movement is large and growing. This bad decision by the House Rules Committee is an affront to the 46 states and the District of Columbia that have legalized use and distribution of some form of medical marijuana. These programs serve millions of Americans. This setback, however, is not the final word. As House and Senate leadership negotiate a long-term funding bill, we will fight to maintain current protections.”

    Since 2014, members of Congress have passed annual spending bills that have included the Rohrabacher-Blumenauer language, protecting those who engage in the state-sanctioned use and dispensing of medical cannabis from undue prosecution by the Department of Justice.

    Most recently, the amendment was reauthorized by Congress in May as part of a short term spending package, in spite of US Attorney General Jeff Sessions aggressively lobbying Congressional leadership to ignore the provisions. At the time of the signing of the bill, President Trump issued a signing statement objecting to the Rohrbacher-Blumenauer provision.

    Without these maintained protections, it is difficult to assess how much business confidence and investment will continue to pour into the nascent industry, which currently serves over 3 million

    However as the Congressmen indicated in their statement, the fight is not over. In July, Senator Patrick Leahy (D-VT) successfully offered and passed the Rohrabacher-Blumenauer amendment in the Senate Appropriations Committee, meaning that the language will be considered in a conference committee despite the fact that the House was denied the opportunity to express it’s support for the 30 states which have legalized medical marijuana and 16 states that have authorized CBD oil access.

    We will continue to advocate for the members who will be in the conference committee to maintain the language from the Senate version in order to continue to serve the millions of men, women, and children who depend on their medication. On Monday and Tuesday, September 11th and 12th, NORML will hold it’s annual Conference and Lobby Day in DC and will focus on the need to not allow our progress to be rolled back – if you can join us in DC, click here to register.

    Keep fighting with us – send a message to your federal elected officials now. 

  • by NORML August 16, 2017

    mj_researchRepresentatives Andy Harris, M.D. (R-MD-01), Earl Blumenauer (D-OR-03), H. Morgan Griffith (R-VA-09), and Zoe Lofgren (D-CA-19) introduced H.R. 3391: The Medical Marijuana Research Act of 2017.

    This Act amends the federal law to facilitate clinical investigations involving the use of cannabis and cannabis-derived products.

    As you may know, there are many benefits to medical cannabis. Those suffering from PTSD, Tourette’s Syndrome, Parkinson’s Disease, and many other debilitating conditions have found relief because of medical marijuana.  

    But, despite the fact that over 200 million Americans now have legal access to some form of medical marijuana, present regulations make clinical investigations involving cannabis needlessly onerous. Passage of this measure would expedite federal reviews of clinical protocols, provide greater access to scientists who wish to study the drug, and mandate an FDA review of the relevant science.

    Please click HERE to contact your Representative and urge him/her to support this important measure.

     

  • by Justin Strekal, NORML Political Director July 19, 2017

    Yesterday, NORML moderated a Facebook Congressional Conversation on marijuana law reform with Representatives Earl Blumenauer, Tom Garrett, Beto O’Rourke, and Justin Amash.

    We discussed a wide range of issues including the needless burden of the federal driver’s license suspension mandate, access to medical marijuana, racial injustice, and pending bipartisan legislation to remove cannabis from the Controlled Substances Act.

    WATCH NOW:

    Share on Facebook  |  Share on Twitter

    The ongoing enforcement of cannabis prohibition financially burdens taxpayers, encroaches upon civil liberties, engenders disrespect for the law, impedes legitimate scientific research into the plant’s medicinal properties, and disproportionately impacts communities of color. Only when lawmakers speak honestly about the effects of prohibition and the senseless burdens it imposes on our communities will we be able to win substantial reform.

    “At a time when 29 states and the District of Columbia have made the decision to regulate the sale and use of marijuana, we should rethink how the federal government approaches this drug. Our current approach to marijuana prevents legitimate medical use, fills our prisons with nonviolent offenders and continues to fuel drug violence,” said Representative Beto O’Rourke in a statement promoting the event.

    In our continued effort to educate the lawmakers and the public, events like this will be able to open the eyes of those who have willfully ignored the issue.

    NORML chapters throughout the country are working to advance legalization in state legislatures and, with your support, National NORML will continue to up the pressure in Washington, DC.

    Click here to share the video through your networks and support efforts like this in the future. 

     

  • by Justin Strekal, NORML Political Director June 29, 2017


    Medical marijuana
    This week, the House Appropriations Committee released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.

    Although the amendment was reauthorized by Congress in May, US Attorney General Jeff Sessions has been aggressively lobbying leadership to ignore the provisions. President Trump also issued a signing statement objecting to the Rohrbacher-Blumenauer provision.

    Nonetheless, support for the Rohrbacher-Blumenauer protection amendment has only grown in recent years. House members initially passed the amendment as a budgetary rider in 2014 by a vote of 219 to 189. By the following year, 242 House members voted in support of the language.

    Yet even with bipartisan support, the text of this amendment has never been included in “the inline text” or “the base bill” of the CJS Appropriations bill. In every case of its passage, lawmakers have needed to add the language as a separate rider to the legislation and then vote on it on the floor of the House.  

    This year is no exception. Our allies in Congress anticipate a similar process to take place this fall and they are confident that we will once again be victorious — despite the best efforts of our opponents.

    Reps. Blumenauer and Rohrbacher last night in a statement:

    “The policy championed by Representatives Blumenauer and Rohrabacher that prevents the Department of Justice from interfering in the ability of states to implement legal medical marijuana laws (previously known as “Rohrabacher-Farr”) has never been included in the base Commerce, Justice, Science, and Related Agencies (CJS) Subcommittee Appropriations bill. Rather, in previous years, Congress has amended the base CJS bill to include these protections.

    We are exactly where we thought we would be in the legislative process and look forward to amending the underlying bill once again this year to make sure medical marijuana programs, and the patients who rely on them, are protected. Voters in states across the country have acted to legalize medical marijuana. Congress should not act against the will of the people who elected us.”

    Thirty states now permit the doctor-authorized use of medical cannabis by statute, and an additional 16 states include statutory protections for the use of CBD. It is hard to imagine a scenario where a majority of lawmakers from these jurisdictions would vote against the best interests of their constituents, given the broad and bipartisan support that the amendment has received in the past.

    It has been and will continue to be in politicians’ best interests to protect this progress and to protect voters’ freedoms from the encroachment of Jeff Sessions and the Justice Department.

    Click here to send a message to your member urging them to support the Rohrabacher-Blumenauer amendment.

    Then click here to tell them to go one step further by urging them to support the newly introduced CARERS Act of 2017 which will codify these protections into law so that we no longer have to have these annual budget fights.

     

  • by Justin Strekal, NORML Political Director April 19, 2017

    NORML held a ‘Faces of Marijuana Prohibition’ event on Capitol Hill on April 19th, in cooperation with the Congressional Cannabis Caucus, where congressional staff heard first-hand from those most adversely impacted by the criminalization of marijuana. 

    Dozens of congressional staff attended, hearing from victims across the spectrum of marijuana criminalization. Perspectives included: a cancer survivor who consumed marijuana to mitigate the effects of chemotherapy, a federal staffer who lost his job as a result of a positive drug test, and those who received criminal charges and had their lives put on hold while they had to overcome the onerous penalties imposed by the state for a simple possession charge, among others. 

    NORML Political Director Justin StrekalThis was yet another effort in our ongoing quest to educate our legislators on the need to to end the prohibition-industrial-complex and respect the basic rights of those who choose to consume marijuana, a substance safer than currently legal products like alcohol or cigarettes.

    Never in modern history has there existed greater public support for ending the nation’s nearly century-long experiment with marijuana prohibition. The continued criminalization of adult marijuana users is out-of-step with the views of adults throughout America, 93% of whom support medical marijuana (Quinnipiac, 2017) and 60 percent of whom endorse the outright legalization of recreational marijuana (Gallup, 2016).

    On April 20th (4/20), long considered the unofficial marijuana holiday, marijuana consumers and advocates will gather around the world to show their support for ending marijuana prohibition. NORML for its part will hosting an online day of action, driving tens of thousands of constituent contacts to members of Congress in support of HR 1227, the Ending Federal Marijuana Prohibition Act. 

    You can sign up for the 4/20 online day of action by clicking here. 

Page 2 of 3123